Home / Transcripts / Yatharth Hospital & Trauma Care Services Limited (YATHARTH) · November 4, 2026

Yatharth Hospital & Trauma Care Services Limited (YATHARTH) Earnings Call Transcript

November 4, 2026

National Stock Exchange of India IN Health Care Health Care Providers and Services earnings 59 min

Earnings Call Speaker Segments

Operator operator
#1

Good day, ladies and gentlemen, and welcome to the Q2 FY '27 earnings conference call for Yatharth Hospital & Trauma Care Services Limited, hosted by Elara Securities. <<operator_script>>. At this point, I'll turn the conference over to Mr. Kashish Thakur of Elara Securities. Thank you, and the floor is yours, sir.

Kashish Thakur analyst
#2

We really appreciate that, Ritija. Good morning to all of you. Elara Securities is pleased to welcome everyone to the Q2 FY '27 earnings conference call for Yatharth Hospital & Trauma Care Services Limited. Joining us are members of the company's senior leadership: Mr. Yatharth Tyagi, full-time director; Mr. Amit Kumar Singh, Group Chief Executive Officer; Mr. Nitin Gupta, President Finance and Group Chief Operating Officer; Mr. Pankaj Prabhakar, Group Chief Financial Officer; Mr. Ashutosh Kumar Jha, Group Chief Strategy, Merger and Acquisition, Investor Relation; and Mr. Sonu Goyal, Group Chief Financial Controller. At this point, I'll turn things over to Yatharth management for their opening remarks. Yatharth sir, the floor is yours.

Yatharth Tyagi executive
#3

Thank you. Good morning, everyone. I'm Yatharth Tyagi, full-time director. It's a pleasure to welcome all of you to the earnings conference call of Yatharth Hospital & Trauma Care Services Limited, covering the quarter and half year that closed on September 30, 2026. The earnings presentation is now available on the stock exchanges as well as on our website. I trust all of you have had a chance to go through it. Now, this marks a significant point in Yatharth Hospital's journey. Quarter two of FY '27 turned out to be our strongest quarter so far, delivering revenue growth of 52% year-on-year along with EBITDA growth of 50%. The hospitals we already operate in Noida, Greater Noida Extension, and Jhansi-Orchha keep posting steady results, with 24% year-on-year revenue growth. These facilities have genuinely driven our profitability, posting an EBITDA margin upwards of 28% for these specific hospitals. Meanwhile, the newer hospitals we have added are steadily ramping up, and they now account for 28% of group revenue, versus 11% in the same period a year earlier. Taken together, these hospitals have gone from an EBITDA loss a year ago to positive EBITDA during H1. It's worth noting that since our listing in August 2023, Yatharth Hospitals has not only more than doubled its capacity from 1,405 beds to about 2,800 beds, but also tripled its revenues and profits.

Yatharth Tyagi executive
#4

During previous updates, we’ve communicated our goal of doubling that capacity once more within the next few years. That said, the healthcare sector presents a far, far larger opportunity. So, in order to speed up our growth path even more, we’ve formed a strategic partnership with Advent International involving a primary capital investment of INR 3,150 crore via a preferential issue of equity shares and warrants. The deal is pending the required regulatory approvals. We see this partnership as far more than merely a capital infusion. Advent has more than 35 years of healthcare investment experience and considerable expertise in building and scaling healthcare platforms. We think this mix of long-term capital and institutional experience will enhance our capacity to chase growth opportunities at greater scale and with discipline. With Advent as a partner, we now intend to build a bigger franchise of 7,000 to 8,000 beds across the next three to five years. We can now proceed faster and pursue larger opportunities while maintaining the same discipline in execution. This partnership also represents a vote of confidence in what our team has built: a growing network, a demonstrated ability to turn around the hospitals we acquire, and a consistent focus on clinical quality.

Yatharth Tyagi executive
#5

I want to recognize the individuals who made this progress possible—our doctors, nurses, management, and every one of our employees—for their dedication, along with our patients and their families for the confidence they have in us, and our shareholders for their ongoing backing as we have grown the network. With that strategic context in mind, our teams stay focused on clinical excellence. In a cluster across Noida and Faridabad, we now rank among the most respected hospitals in that area. In Greater Noida, our teams treated a rare liver condition and, in one sitting, reconstructed two nerves for a brachial plexus injury—a procedure that very few centers in the region provide. At Faridabad Sector 20, we opened the region's first memory clinic. In recognition of clinical excellence, we received the Hospital Excellence & Innovation Award at the Health & Wellness Excellence Awards 2026 from the ASSOCHAM organization. Our Noida and Greater Noida hospitals placed among the top in the Noida-Ghaziabad region in Times of India ranking. We were recognized across multiple specialties in the Outlook Best Hospital Rankings 2026. Now moving to the operating highlights for the quarter. Our ARPOB climbed 11% year-on-year to roughly INR 36,000. Our occupancy was healthy at 72% on the beds currently operationalized.

Yatharth Tyagi executive
#6

As we ramp up, roughly 350 to 400 beds still need to be operationalized across Faridabad, Model Town, and Agra, which offers meaningful headroom for growth. While existing hospitals keep compounding, our newer hospitals are scaling nicely and adding more to the network each quarter. Faridabad Sector 20 demonstrates what our acquisition and turnaround playbook is capable of delivering. That hospital reached EBITDA positive in a record period and brought in revenue of approximately INR 40 crore during the last quarter. Over 80% of its business is driven by cash and private insurance patients, with ARPOB of approximately INR 40,000. Our New Delhi hospital at Model Town is on the same trajectory. In quarter 2, it posted revenue of approximately INR 26 crore and ARPOB of around INR 50,000, putting it among the premium hospitals in NCR, together with Noida Extension, where ARPOB has also gone past INR 50,000. We expect the Model Town Hospital, Delhi, to break even in the second half of this financial year. Agra, our first corporate hospital in that region, has improved steadily since we took it over. In Q2, the hospital stayed EBITDA positive on revenue of approximately INR 20 crore. Next is Gurugram, our upcoming 250-bedded hospital in Sector 40, which is progressing well and is expected to operationalize in the next financial year.

Yatharth Tyagi executive
#7

For the hospital, we anticipate it will cater to the premium Gurugram market. Its location sits within a catchment of strong potential, and it is close to Delhi airport, so we expect an ARPOB above INR 50,000. We'll keep assessing additional expansion opportunities, looking carefully at strategic fit, quality, and returns. Our model has already been proven, our network is generating both growth and profitability, and we have the resources to extend it further. Our goal is a high-quality, scaled healthcare network, and to create lasting values for all our shareholders. We enter this next phase from a position of strength, confident in what lies ahead. Thank you again for your continued trust and support. I'll now hand over to our Group CFO, Mr. Pankaj Prabhakar, who will walk you through the financial performances in greater detail.

Pankaj Prabhakar executive
#8

Thanks, Yatharth, and good morning, everyone. I'll walk you through how the group performed financially and operationally in quarter 2 and H1 FY '27. In Q2 FY '27, the group brought in its highest quarterly revenue ever, INR 4,314 million, which works out to 52% growth year-on-year and 10% sequentially. For H1 FY '27, revenue came in at INR 8,241 million, up 52% year-on-year. That result mirrors what our established hospitals add along with the growing scale of our newer facilities. Our existing hospitals — Noida, Greater Noida, Noida Extension, and Jhansi-Orchha — delivered INR 3,109 million in quarter 2, a year-on-year rise of 24%. Inpatient volumes at these hospitals were up 28%, and occupancy climbed to 78% from 71% a year earlier. Occupancy at Noida and Jhansi-Orchha came in above 90%, whereas Greater Noida posted 78% and Noida Extension 61%. Our newer hospitals — Greater Faridabad, New Delhi, Faridabad Sector 20, and Agra — added INR 1,205 million, equal to 28% of group revenue. Greater Faridabad recorded a healthy 77% occupancy. Faridabad Sector 20, Agra, and New Delhi are still ramping up their operational census bed. Group ARPOBs hit an all-time high of INR 36,000, an 11% increase year-on-year. Noida Extension and New Delhi each posted an ARPOB of approx INR 50,000, Greater Noida approximately INR 43,000, Faridabad INR 40,000, Noida INR 47,000, Greater Faridabad INR 35,000, and Agra INR 33,000.

Pankaj Prabhakar executive
#9

With our newer and premium hospitals continuing to scale up and the specialty mix getting better, we anticipate a meaningful improvement in group ARPOB over the years ahead. Now on margins and profitability. Quarter 2 EBITDA came in at a record INR 1,020 million, which is up 50% year-on-year and 11% quarter-on-quarter. EBITDA margin rose to 23.6%, helped by the newer hospitals running profitably. If you exclude the ramp-up losses at New Delhi and Faridabad Sector 20, our adjusted EBITDA margin was a healthy 28%. Profit after tax for quarter two was INR 485 million, 17% higher year-on-year, and INR 939 million for H1. Cash profit, though, which adds back depreciation to the PAT, was actually up 36% year-on-year. Operating cash flow for H1 came to INR 1,113 million, a rise of 49% year-on-year. As of September 30, 2026, cash and bank balances were INR 4,289 million, while net debt was INR 392 million. That gives us a comfortable balance sheet position as we keep investing in the network and get ready for the next phase of expansion. To sum up, quarter two and H1 FY '27 have been defined by strong revenue growth and growing contributions from our newer hospitals.

Pankaj Prabhakar executive
#10

Cash generation has stayed healthy as well, and our leverage position remains comfortable. Through the proposed partnership with Advent, we feel we're in a strong position to go after the next stage of growth, while keeping our focus on execution, returns, and quality of care. I appreciate your time. At this point I'll turn the call back to the moderator for the question and answer session. Thank you.

Operator operator
#11

Thanks a lot. <<operator_script>> Our first question comes from Aryan Jain at Groww Mutual Fund. Kindly proceed.

Aryan Jain analyst
#12

Yeah. Hi there. Thanks for giving me the chance to ask, and congratulations on such a strong set of numbers. So my first question is this: what would your payer mix look like for this quarter?

Yatharth Tyagi executive
#13

Payer mix came in at roughly 34% for this quarter, a few percent lower than what we saw last quarter.

Analyst analyst
#14

That falls under our government institution business.

Yatharth Tyagi executive
#15

So that's the government institution side, and the remainder splits about evenly between private insurance and cash-paying patients — private insurance is a few percentage points above the cash business. International business is still around 4%-5% at the present payment level.

Analyst analyst
#16

You mentioned 34%, correct? That was for the government mix. What did it come to last year?

Yatharth Tyagi executive
#17

The government mix came in at 34% for the quarter, compared with 37% in the prior quarter.

Analyst analyst
#18

Got it. For my second question — apologies if this was covered in the opening comments — what are the occupancy levels at Delhi, Faridabad, and Agra?

Nitin Gupta executive
#19

We've pushed occupancy up on a blended basis — it went from 68% last quarter to 72% this quarter. That said, on Model Town, as you've been pointing out, it's climbed to 41% this quarter. At the new Faridabad hospital, it's risen to 59%, and Agra currently sits at 58%.

Analyst analyst
#20

Alright.

Ashutosh Jha executive
#21

One more thing worth pointing out: not every bed in those hospitals is up and running yet, so some still have to be opened.

Analyst analyst
#22

Right, that was actually the follow-up I had. Given occupancies now sit closer to 60%, are there any timelines for opening more of the remaining beds?

Ashutosh Jha executive
#23

My expectation is that over the coming two to three quarters — perhaps within the next couple of quarters — all of the beds should be open.

Analyst analyst
#24

All right, just one final question. How much of our total revenue would the pharmacy business account for?

Amit Singh executive
#25

I think a lot of procedures come bundled with the packages and everything, so we don't calculate it, and we don't view it that way as a pharmacy business standing on, right? If the questions were meant to draw some inferences about that — what's going on in the government and the court comments on all these things — I think it's very premature as of now. That's how it's being directed. I think the industry has also represented that the government is part of it. Let's see how it goes up. Just giving you this thing, I think we don't look at it that way, the absolute pharmacy percentage.

Analyst analyst
#26

All right, got it. Thanks. I’ll get back in line for any additional questions.

Operator operator
#27

Thanks. Our next question comes from Praveen at Fortune Tower Investment, on the line now — please go ahead.

Analyst analyst
#28

Hi there, sir — is my voice coming through clearly?

Amit Singh executive
#29

Yes.

Analyst analyst
#30

Morning, and nice work on those results. Let's tackle the obvious question first. Could you share what impact the cap on cancer medications will have on both your top line and your bottom line? That's my first one. And for the second: are there any new assets in the works for this year? Also, when do you expect the Advent deal to close? Thanks—those are my two questions. Thank you.

Yatharth Tyagi executive
#31

Regarding your first question about the cap on a specific list of cancer drugs, we've done our homework. We've worked out that with the current list for cancer capping, where margins stand at 30%, the total effect on our EBITDA figures comes to roughly a 0.3% decrease stemming from that particular pricing on the onco product. That said, despite this 0.3% decrease attributable to cancer drugs, our guidance for EBITDA at the overall company level — which sits near 24% across the quarters and years ahead — stays as it is. Since we have this 0.3% reduction in cancer, we're already working it out and developing strategies to offset it through other operational efficiencies and line items, along with other means of compensation. Our EBITDA at the overall group level will not change going forward as a result of this policy.

Analyst analyst
#32

Got it, thanks. Would you mind addressing the second question — the Advent deal?

Yatharth Tyagi executive
#33

Yeah, I believe the Advent deal is in the final stages of CCI approvals. After Diwali, we can expect approval to come through this very month, I think. We're looking forward to it.

Analyst analyst
#34

Okay, yes, thanks a lot. I hope everything goes well for all of you, and that your hospitals can treat even more people. Many thanks.

Operator operator
#35

Thanks. Our next question comes from Shrikant Akolkar at Nuvama. Please go ahead.

Shrikant Akolkar analyst
#36

Hi, good morning. Thanks for taking my question. Regarding the Advent deal, I just want to know how many tranches they'll get this money in?

Ashutosh Jha executive
#37

Yes. The INR 3,150 crore from Advent is going to arrive in two tranches. The initial tranche is INR 1,750 crore, and it'll be received once CCI approval comes through this month. Then the second tranche arrives 15 to 18 months later, subject to certain conditions. So that's regarding how the funds get utilized.

Shrikant Akolkar analyst
#38

Got it. Now turning to the expansion strategy, since we also have a strong partner. So how are we approaching expansion? Regarding the asset's size, and perhaps potentially ARPOB — the kind of ARPOB we'd consider — if it's multi-specialty, single specialty, or perhaps a standalone hospital or a chain of hospitals. So what should our strategy be?

Ashutosh Jha executive
#39

We're still concentrating on multi-specialty hospitals. At this point, naturally, we're examining significantly bigger transactions, and a hospital chain is also something we're seeking. What I mean is, we want hospitals that potentially could deliver a better ARPOB than ours. North India is our priority as we search across it, and we're open to other regions too should a hospital chain be available there.

Yatharth Tyagi executive
#40

In addition, the properties we keep buying from this particular fund are going to be hospitals that are EBITDA positive without exception. You won't see any outright hit to absolute EBITDA from these deals as we move forward.

Shrikant Akolkar analyst
#41

Got it. On the timeline, you've mentioned wanting to more than double capacity within the next three to five years. Meanwhile, our own expansion is already underway, and we now have extra money available. If you could go into a bit more detail on this, how many beds will be added next year, and perhaps a schedule — even a broad one — that would really help us.

Yatharth Tyagi executive
#42

We don't really have guidance for a specific one-year or six-month period. As for how the expansion breaks down, under our existing organic plan we had announced reaching 5,000 beds of capacity over roughly three to four years ahead. That stays the same. Beyond that, we expect to add around 2,000 to 3,000 beds as a result of this recent deal, again within somewhere close to four years ahead.

Shrikant Akolkar analyst
#43

Got it — and thanks a lot for getting back to me. I appreciate it.

Operator operator
#44

Thanks. Our next question comes from Aanchal Maheshwari at Naredi. Go ahead, please.

Aanchal Maheshwari analyst
#45

Sir, if I may ask, could you go over the ARPOB figures for each hospital once more?

Nitin Gupta executive
#46

Sure. As we mentioned, the blended ARPOB for this quarter came in at close to INR 36,000. We're also glad to report that the top ARPOB was recorded at the Noida Extension Hospital, at roughly INR 51,000. Similarly, Delhi stood at about INR 47,000. That's followed by Greater Noida at INR 43,000 <<inaudible>>, Greater Faridabad at INR 33,000, Noida at INR 37,000, the new Faridabad Hospital at INR 37,000, Agra at roughly INR 33,000, and Jhansi at about INR 14,000.

Analyst analyst
#47

I really appreciate it.

Nitin Gupta executive
#48

Year over year, ARPOB grew by roughly 11%.

Analyst analyst
#49

Okay, thanks a lot.

Operator operator
#50

Thanks. The next question comes from Surya Narayan Nayak at Sunidhi Securities. Your line is open — please go ahead.

Surya Narayan Nayak analyst
#51

Hi there. Nice work on those strong results. I have one question: given that EBITDA-to-CFO conversion has historically been 70%, we've noticed a bit of softness this quarter and this half. Since the payer mix has also gotten better relative to last year, when should we expect improvement? What's your view on that?

Ashutosh Jha executive
#52

Surya, typically H1 collections come in below what we see for the whole year. That's the reason you'd notice a modest dip in the OCF conversion rate. Still, once the year wraps up, we should be looking at conversion above 70%.

Surya Narayan Nayak analyst
#53

Second, you're saying that you're seeking out hospitals whose ARPOB potential is actually above ours. So in that case, given the cash flow, or the cash on hand, that you have, will your position on raising bed capacity past 5,000 still hold?

Ashutosh Jha executive
#54

Yeah, the plan we already have—5,000 beds organically, funded through our internal resource accruals—stays exactly as it is. As for the extra money coming in from Advent, that's really aimed at pushing the growth further, as we've said, toward acquiring roughly 2,000 plus beds.

Surya Narayan Nayak analyst
#55

So those 2,000 beds, which year are they planned for? Is that an FY '28 or FY '29 scenario?

Yatharth Tyagi executive
#56

The way we see it, those roughly 2,000 beds in total ought to be generating the combined revenue within the coming three to four years. That said, on the acquisition side — since the first tranche is arriving sometime this month, we want to put that first tranche to work as quickly as we can. So perhaps about 40%-50% of those beds could actually come online starting in the next financial year itself.

Surya Narayan Nayak analyst
#57

All right. Could you provide some sense of the momentum? We have a certain picture through FY '28, but what would the incremental flows look like as far as P&L traction from FY '29 onward? If you're able to guide on that, since I understand that some of it now will depend on the kinds of hospitals we're going to acquire. So if it's a running hospital, then obviously the CAGR will be improving, and obviously there won't be an EBITDA drag. But if you could give some color for FY '29's sake, because we have clarity through FY '28.

Yatharth Tyagi executive
#58

On the current organic plan, 30% revenue growth on a y-o-y basis is clearly achievable over the coming three to four years, prior to the Advent deal. So that trend will carry on as it is. What we expect — the way we're viewing it — is that we haven't set a one- or two-year target. Our view is that the INR 3,150 crore in additional funds will go toward acquiring more assets with absolute EBITDA and revenue. That comes on top of, and beyond, the existing plan. Even with our current plan of 30% revenue growth over the next 3.5 years — roughly 2.5x — if you add the INR 3,150 crore of deployment, EBITDA can readily be layered on top of that 2.5x, and that should comfortably take us past 3x versus today's numbers within the next 3.5 to 4 years.

Surya Narayan Nayak analyst
#59

Finally, from Model Town’s perspective, when that ramp-up occurs—say occupancy climbs to near 50%–60%—are you running into any competition in that property’s area?

Yatharth Tyagi executive
#60

Regarding Model Town, yes, a couple of hospitals are located there, but our thinking on where we stand is quite clear. It's an extremely — largely populated area, correct? So very densely populated. Up to now, growth has been very good. I think next quarter, probably at the quarter's end, this should be EBITDA positive.

Surya Narayan Nayak analyst
#61

I appreciate that.

Operator operator
#62

Thanks. Our next question comes from Khush Jain at Neev Money. Go ahead, please. Mr. Khush Jain, your line is unmuted, so please proceed with your question.

Khush Jain analyst
#63

Is my voice coming through?

Operator operator
#64

Correct.

Analyst analyst
#65

First question, sir, about medical tourism. What’s your plan for raising the share of international patients in total revenue? Which overseas markets are you going after, and what incentives are you using to draw in more patients—things like tie-ups with hospitals abroad or international healthcare agencies? Also, what targets do you have in mind for the coming three to five years, and in what ways could this segment lift your ARPOB, revenue growth, and overall profitability?

Amit Singh executive
#66

On the international side, we began concentrating on overseas markets during the last financial year, correct? I feel quite pleased seeing the kinds of strategic alliances and partnerships we formed across various international markets. I think those efforts have started to pay off. To put it in perspective, comparing H2 of last year with H1 of this year, our international business grew by more than 35%. Even so, it remains in a single digit relative to the top line, but we are making a very significant move, and various areas such as CIS are contributing. That said, it has been affected over the last couple of months because of the war, Gulf and other things. Even so, I think we are making very steady progress in this region. CIS particularly, and the African market is contributing very well, correct? Lots of tie-ups that we have completed, whether it is Mauritius, whether it is Ethiopia, South Sudan, another region. So we have channel partners there. There are a couple of alliances we have also done with the hospitals, correct? So we are doing well, and as far as contribution is concerned, I think that is the ARPOB always -- and all of us know that the international business contributes a very high ARPOB.

Amit Singh executive
#67

So I'd say things are tracking in line with what we expected. The coming 3 to 4 years are going to be fantastic, because Noida airport still hasn't opened up for the international market. That's going to be a significant addition for us, and that's what we're hoping for. We also have a strong plan when it comes to international. A dedicated team is working on that. So it looks very, very positive.

Analyst analyst
#68

Yes, that's an interesting one. So the next question concerns Advent International. Regarding Advent International, what would the CapEx per bed come to for the greenfield expansion that you're planning?

Yatharth Tyagi executive
#69

So for the most part, we don't intend to carry out any significant greenfield expansion using the funds that came in from Advent. As we mentioned, our approach is to acquire assets that are already running and that are EBITDA positive, and from that sum, the overall bed capacity we could potentially add ought to come to roughly 2,000 beds altogether.

Analyst analyst
#70

All right, so starting from INR 3,000 crore, you could pick up another 2,000 beds on top of that. Right? Is that correct?

Yatharth Tyagi executive
#71

Yeah, that's about right — close to that figure.

Analyst analyst
#72

Thanks.

Operator operator
#73

Thanks. Our next question comes from Akshat Mehta at Seven Rivers Holding. The line is yours — please proceed.

Akshat Mehta analyst
#74

Hi there, sir. Can you hear me okay?

Yatharth Tyagi executive
#75

Yes.

Akshat Mehta analyst
#76

Hello there, and thanks for the kind words about the results — good to hear. I have a few questions about the business. First, we've noticed that your gross debt figure has been climbing, both at the close of FY '26 and at the end of H1 as well. I'd just like to get a sense of where that debt is headed and what kind of repayment we should expect over the course of the year?

Yatharth Tyagi executive
#77

When it comes to total debt, the increase since the last financial year has mainly come from the INR 100 crore we spent on the Gurugram facility. On top of that, roughly INR 100 crore or more has been drawn for certain medical equipment, which has been added to both the Model Town Hospital and the Sector 20 Faridabad Hospital, as well as for certain construction already in full swing at the Gurugram Hospital. That said, we believe this represents the peak level of debt for us, at least over the next few quarters. Debt will definitely, eventually, be able to come down from here as well. We also feel that going forward, even though the entire focus is on acquiring new hospitals with the Advent money, if the acquisitions take time with respect to certain assets, we can also briefly look at reducing debt from that amount too, at a minute level, by a small amount. I think this is the peak level of debt that the company expects in the coming quarters.

Akshat Mehta analyst
#78

Alright, so my next question, sir, is about your Agra hospital, sir. What's going on there? During one quarter, occupancy has dropped quite sharply, but at the same time your ARPOB has risen as well. Are we looking at a mix change — a significant mix change in Agra? What's happening there?

Yatharth Tyagi executive
#79

When it comes to Agra, we're quite pleased with the figures and with how that hospital has ramped up and scaled well. We've become the most preferred hospital in that area. I can also say that the volume of robotic surgeries we're performing in Agra is probably at par with, or even higher than, certain NCR hospitals. Without question, Agra is now on a monthly trend similar to what it was in quarter one, as well as in the earlier months of quarter two. I think going forward, we're not just optimizing payer mix there, but we're also in line to renovate the facility as well as add certain more beds, and certain floors are in a renovation stage there as well.

Akshat Mehta analyst
#80

On the case mix side, or regarding treatments — have any new additions been made, or is there anything you plan to add in Agra?

Amit Singh executive
#81

Yes, absolutely. We recently brought in CTVS surgery and cardiac surgery. We recently -- we're also planning on adding pediatric cardiac. And we're strengthening a couple of specialties that we felt weren't quite up to the mark. That work is underway, and as I just mentioned, robotics is happening there too. I think in a way, we're largely doing everything except, as you say, radiation onco and the transplant program, but Agra is doing well. Yes, a few changes are going to happen, depending on how the specialties or the department perform in the future.

Akshat Mehta analyst
#82

All right, final question for you. Could you update us on the IT issue, sir? After that, we saw the demand notice. What has taken place since, and what is the formal plan?

Yatharth Tyagi executive
#83

I believe, as we mentioned, that the IT issue has been settled, and after that we got the final demand…

Akshat Mehta analyst
#84

Alright.

Yatharth Tyagi executive
#85

From what we were saying, the final demand has arrived and the matter is now resolved. There had been no — previously as well, all the assets and the FDs were released for the company. As far as even going forward is concerned, because even the existing demand, we feel, can be significantly reduced. That is the only reason we feel that, and because of taking legal opinions and even with the talks from the department itself, we have been advised to go into appeal against that. However, it is a normal course of appeal. It is not that the whole matter is still pending at a larger scale. The capping has been done as far as the demand is concerned, and we also feel that this will significantly reduce. That's what we are doing, and we expect this also to reduce in the coming quarters ahead.

Akshat Mehta analyst
#86

All right, sir. Thanks, and congratulations again.

Operator operator
#87

Thanks. Our next question comes from Meet Mehta at Entigrity Ventures and Partnerships. Go ahead, please.

Meet Mehta analyst
#88

Yeah, hi, team. Congrats on a great set of results. My first question concerns the onco status at the Model Town and Faridabad hospitals. When do we expect the oncology segment to go live at both of those hospitals?

Amit Singh executive
#89

Faridabad, I believe everything is wrapped up at this point. The equipment is already in place. Right now it's just some formalities with the AERB. We're looking at 40, 45 days. So we're on the final stretch of all this. The clinical manpower is already on board, correct? So we'd expect that over the next 45 to 60 days, the whole spectrum — the oncology, medical and surgical — we're already doing that. So radiation and nuclear, we're going to begin within the next two months. So, that's Sector 20. Model Town is going to take some time. I think as of now it's still at the drawing stage, because we have to complete — we have to set up everything new for this whole radiation piece, the bunkers and all, since in Faridabad it was already in place. Here we need to build it. So it's in the planning phase. I think the drawings have already been done. So we'll work it out. As you know, Delhi now has GRAP 2 in effect, so construction is on hold. So it'll probably take two, three months before we can start our work. So we'll share again in another six months.

Yatharth Tyagi executive
#90

That said, medical and surgical oncology are already up and running at Model Town. Not long ago, we brought on some standout physicians in oncology for those specialties, and the volumes we're seeing are already solid. As Amit said, radiation oncology will be added at that hospital. My sense is the timeline lands at roughly eight to nine months.

Aryan Jain analyst
#91

Understood. Are we on schedule to reach break-even at the Delhi Model Town Hospital?

Amit Singh executive
#92

We mentioned that in the coming quarter, I believe we ought to be. Delhi is very much performing in line with what was expected. In the next quarter, I think Delhi should be <<inaudible>>.

Pankaj Prabhakar executive
#93

Looking at Model Town, the losses have gone down from one quarter to the next. In Q1, the loss came to INR 55 million. This quarter, we posted a loss of INR 38 million. And for the coming quarter, we're quite confident that December will be a break-even month for the Delhi quarter — for the Delhi hospital.

Akshaya Shinde analyst
#94

Understood. Finally, regarding the bed additions, is there anything to share about the Noida hospital, the Greater Faridabad Hospital, and the Jhansi Hospital? The reason I ask is that we're getting close to optimal utilization of capacity. Any details on those three facilities?

Yatharth Tyagi executive
#95

Those 3 hospitals don’t leave much room for growth. That said, we do expect a slight improvement in ARPOB there, and we’re also focused on the payer mix at those facilities. Even so, we have no particular plans for brownfield capacity expansion at those hospitals.

Prashant Sharma analyst
#96

Okay. Are there any additional hospitals we're considering within those regions?

Yatharth Tyagi executive
#97

Like we mentioned, our goal is a very large expansion of capacity when it comes to adding new hospitals and new beds. We're concentrating on additional parts of the NCR, on micro markets within the NCR where we don't yet have a presence, and on a bigger scale throughout the entire North India market. In particular, we continue to believe that U.P., Haryana, Punjab, and naturally Delhi NCR offer solid room for growth. As I noted, with the Advent deal now in place, our horizons have widened. The north is still the priority, though if a strong cluster of hospitals becomes available beyond the north, we will be actively evaluating it.

Akshaya Shinde analyst
#98

Yatharth, congratulations on those strong results, and best wishes going forward.

Operator operator
#99

Thanks. Our next question comes from Aryan Jain at Groww Mutual Fund. You have the floor.

Analyst analyst
#100

Yeah, hi, and thanks for following up. First thing I wanted to ask: has anything shifted with the 24% plus margin guidance we gave for the year, considering that both of the new assets are actually ramping up faster than expected?

Yatharth Tyagi executive
#101

My view is that the guidance stays the same. In fact, we also need to make up for the gap created by the differences in oncology pricing. Even so, we remain confident that our guidance for EBITDA margins will stay unchanged.

Analyst analyst
#102

All right. Given that Gurugram is coming online next year and the Advent funds will also be put to work next year, should we be thinking of margins as roughly flat across the next couple of years, starting from the FY '27 level?

Yatharth Tyagi executive
#103

We haven't put together a blended margin plan, since that's going to hinge on what kinds of assets and what kinds of deals we can close from the first tranche we receive. What we are projecting, though, is our current plan, in which EBITDA margins keep trending upward but sit above 24% for the years ahead. As for blended margins from the new hospitals, those will rest on the kinds of deals we manage to close.

Amit Singh executive
#104

Keep in mind that our current hospitals—Faridabad and Delhi especially—will begin offsetting whatever drag there might be.

Analyst analyst
#105

All right, understood. Just one final question from me. Considering how competitive that market is, how quickly do we anticipate the Gurugram facility reaching break-even?

Yatharth Tyagi executive
#106

Regarding Gurugram, our aim is likewise to reach break-even within 15 months. That said, it will be a facility with a very high premium ARPOB, along with a very high payer mix consisting of cash and private insurance as well as international patients. On the break-even point, I think 15 would be squarely on the conservative side.

Analyst analyst
#107

All right, I appreciate it. That covers everything I wanted to ask.

Operator operator
#108

Thanks. The next question comes from Akshaya Shinde at Centrum Broking. Go ahead, please. Akshaya Shinde, please proceed with your question. Your line isn't muted. Akshaya Shinde, could we ask you to unmute yourself and go ahead with your questions. Since there's no response, we'll move on to the next question, from Praveen at Fortune Tower Investments. Please go ahead.

Analyst analyst
#109

Sir, thanks for taking the follow-up. Sir, my question concerns your next phase of expansion. So, what type of assets would you be more keen on? Would you be more interested in buying additional operational assets, or do you want to stick with this operational maintenance asset-like model? If both are planned, could you help us with what the breakup would look like, please? Thank you.

Yatharth Tyagi executive
#110

Yeah, I think it would be a combination of both, though mainly they'd be assets that are 100% equity-owned. Given the substantial capital we need to put to work right now, we're able to consider bigger hospital chains to deploy into. There are a few hospital chains available within the North market itself that we're capable of and are evaluating. Those are largely asset-owned — chains of assets that are 100% equity-owned. I think, yes, moving forward, we could even look at having certain hospitals available on O&M, but those would mostly be standalone hospitals, which would largely be part of the initially 5,000-bed capacity expansion we're concerned with. But when it comes to the new Advent capital, it would mostly be fully owned assets.

Analyst analyst
#111

Appreciate it. Thanks for the response.

Operator operator
#112

Thanks. Our following question comes from Prashant Sharma of Hem Securities. You have the floor.

Analyst analyst
#113

Good morning, everyone. Sir, during the earlier call you spoke about reducing the government business from 35% to 20%, and about retaining government business in specific ways — for instance, at 20% in the newer hospitals. Sir, are we pursuing that pattern at the new hospital, and what would the outlook be for government business over the coming two to three years, sir?

Yatharth Tyagi executive
#114

Looking at how Model Town and Sector 20 Faridabad have performed, and even Greater Faridabad — which was the most recent one before those two — you can already see that at the two new hospitals, government business accounts for no more than 15%-20%. So we aren't just sticking to that playbook; we're also demonstrating the results from it. As these hospitals scale up, that's going to be a significant help in getting us to that initial target for government business. Gurugram should follow a similar path next year once it opens. So I'd say we're very much on that trend, and the guidance there stays the same.

Analyst analyst
#115

Alright, sir, thank you. That's everything from me, sir. Wishing you all the best, sir.

Operator operator
#116

Thanks. The next question comes from Akshaya Shinde at Centrum Broking. Go ahead, please. Akshaya Shinde, please proceed with your question. Your line isn't muted. Akshaya Shinde, could we ask you to unmute yourself and go ahead with your questions. Since there's no response, we'll move on to the next question, which comes from Rushikesh Bhoi at Purnartha Investment Advisers. Please go ahead.

Analyst analyst
#117

Yeah. Hi. Thanks for the chance to ask. I've just got one question about the oncology share. So, a hospital quite close to Greater Noida recently opened a comprehensive cancer care center. Are you feeling any pressure from these oncology patients <<inaudible>> when it comes to keeping oncology talent there?

Amit Singh executive
#118

In Greater Noida, I think, when it comes to the full scale of oncology, I think, aside from that one hospital that has more of the medical college, I don't think any other hospital has got it, but Noida has got a couple of hospitals when it comes to the full spectrum of onco. What's your second question? I missed that, the second part of it.

Analyst analyst
#119

Alright, the next thing I'd like an update on — what's the situation right now with the Gurugram Sector 40 facility as far as construction goes?

Ashutosh Jha executive
#120

Regarding construction, we're renovating the current building, and in a sense, we're adding capacity there as well. The plans have also been submitted, and we've begun altering the existing building in line with the plan. Once the plan approval comes through, we'll begin construction on the rest of it.

Yatharth Tyagi executive
#121

This facility is being built at the very premium end. We've opted for some of the biggest room sizes of any hospital in the Gurugram market. I think we're eagerly awaiting this facility's full launch.

Analyst analyst
#122

All right, let me just add my first question. I believe you skipped the second one. On that question, are you noticing any strain when it comes to oncology patient footfall, or in keeping oncology talent in Greater Noida, in the … area?

Yatharth Tyagi executive
#123

No, in Greater Noida we technically have two hospitals, since Greater Noida and even Noida Extension — Noida Extension is technically Greater Noida West as well. So both of those facilities are serving the highest number of oncology patients compared with any other hospital in Greater Noida. So I think we don't see any impact. In fact, if you look at it, the absolute volume of our oncology business has gone up at both of these hospitals. We're also adding more doctors, including leading doctors from NCR. As far as oncology goes, we have planned additions at these two hospitals. So up to now, there's no impact in terms of volume.

Analyst analyst
#124

All right, and what about on the talent side?

Amit Singh executive
#125

I believe we already have a sufficient supply of doctors, correct? So, we currently operate eight hospitals and possess adequate patient volumes—adequate physician resources as well. And then, as you observe additional hospitals increasingly appearing in that specific area, it likewise draws clinical expertise. So, I think that will not be—I think a clinical shortage does not exist within that particular market. And we feel highly confident that in Greater Noida, once we have our full spectrum in place, which is very soon—we are going to add nuclear as well as radiation oncology at the Greater Noida facility too. So, regarding the doctor level, I do not think there will be any challenge.

Analyst analyst
#126

All right, understood. Appreciate it.

Operator operator
#127

Thanks. Our next question comes from Kashish Thakur at Elara Securities. Please go ahead.

Kashish Thakur analyst
#128

Hello, sir. Thanks for the chance to ask. One question. Sir, how are we approaching the Supreme Court's ruling — the one suggesting that alongside onco, we ought to have caps on other drugs too? That would likely eat into a lot of our profitability and so on. I just wanted to hear your perspective on that side of things.

Amit Singh executive
#129

No, as I mentioned during my earlier remarks, nothing has come up yet. Discussions are taking place. Since the matter is before the court, we'd prefer not to comment on it as such. But yes, as I said, the hospital industries have already put forward their representations, and talks are ongoing. What is going to happen, we don't know. Still, I think whatever happens will be for the best, and the industry and the government will definitely be in discussions, and we have made our representations. Not much to comment on it, but whenever it happens, we'll see accordingly and then we'll plan.

Yatharth Tyagi executive
#130

Look, as an organization, we've always tried to restructure and evolve our strategies in line with regulatory policies and new frameworks. Just like in oncology — yes, there was a marginal, small impact for us, but that impact wasn't high. But even so, we've already worked on certain other line items and operational efficiencies so that our EBITDA target guidance doesn't change. So I think with any regulatory policy changes going forward, maybe in pharma or any other aspect, we would be looking to evolve our strategies and our work, still trying to meet the guidance that we have for the next few years.

Kashish Thakur analyst
#131

That was quite useful. Many thanks.

Operator operator
#132

Thanks. The next question comes from Meet Mehta of Entigrity Ventures and Partnerships, on the line. Go ahead, please.

Meet Mehta analyst
#133

Thanks for the follow-up question. I was hoping to get a feel for the CapEx per bed. In the past, we've bought assets that were stressed. Could you share some detail on what CapEx per bed we're targeting for the next phase of expansion now that the Advent money is coming in? Any view on that would be helpful.

Yatharth Tyagi executive
#134

I think it's really because of the Advent money specifically that we aren't building any greenfield assets, and we may not pursue absolute stress assets either. We'd be going after assets that, yes, would carry huge upside and potential for them. They wouldn't be saturated hospitals. But what we're seeing is more in terms of total bed capacity as well as the absolute EBITDA we can add. Based on the options we've purely evaluated, and certain additional options could come up going forward, we feel close to 2,000 beds can be added — but it shouldn't be viewed purely on CapEx per bed from just the bed angle, because those 2,000 beds would contribute significantly to the top line and the EBITDA. I think that's where the real value will come from, and not just from the bed addition of this further expansion.

Sanath Vaze analyst
#135

Yeah. Yeah, that helped, and thanks.

Operator operator
#136

Thanks. The next question comes from Sanath Vaze of Centrum Broking, who is on the line. Please go ahead.

Analyst analyst
#137

Hello, sir. Can you hear me?

Operator operator
#138

Yes, please feel free to proceed.

Analyst analyst
#139

Yes. Since you favor buying hospitals that are large and EBITDA-positive, what types of assets and valuation multiples are you aiming at right now? And secondly, how do you think about paying a premium for hospitals that carry greater growth potential?

Yatharth Tyagi executive
#140

Look, I think it's really hard to attach a specific figure to how many multiples these deals will end up at. The way we see it, if a hospital has strong upside potential in terms of where it stands and we can genuinely expand it, that alone is the biggest criterion. On top of that, the premium really hinges on the percentage of growth a hospital can achieve. And there's another factor we can weigh when it comes to paying a premium over valuation: whether that hospital's average revenue per occupied bed exceeds our group average, or whether the payer mix at that hospital or hospital chain carries a larger share of cash and private insurance than even our current platform does. So that, too, becomes an additional criterion for us when considering a premium where deals are concerned.

Analyst analyst
#141

Alright, thank you, sir.

Operator operator
#142

Thanks. Our next question comes from Shubham Rai, an individual investor. Please go ahead. Mr. Shubham Rai, please go ahead with your question. Your line is unmuted. Mr. Rai, could we ask you to please go ahead with your question? Your line is unmuted. There is no response from the participants, and since there are no further questions from the participants, I now hand the conference over to management for closing comments.

Yatharth Tyagi executive
#143

Thanks, everybody, for this H1 presentation. I'm looking forward to the next quarter's results and to seeing you soon. Thank you.

Amit Singh executive
#144

Thanks to all of you.

Operator operator
#145

Thanks. That wraps up this conference on behalf of Elara Securities. We appreciate you being with us, and at this point you can go ahead and disconnect your lines. Thank you.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Yatharth Hospital & Trauma Care Services Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Yatharth Hospital & Trauma Care Services Limited earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.